Cowen reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note released on Tuesday, The Fly reports.

Separately, BTIG Research began coverage on Y-mAbs Therapeutics in a research report on Tuesday. They issued a buy rating and a $35.00 price target for the company.

NASDAQ:YMAB opened at $22.00 on Tuesday. Y-mAbs Therapeutics has a 1-year low of $18.00 and a 1-year high of $31.00.

In other Y-mAbs Therapeutics news, CEO Moller San Pedro Claus Juan acquired 31,250 shares of the firm’s stock in a transaction on Tuesday, September 25th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James Healy acquired 500,000 shares of the firm’s stock in a transaction on Friday, September 21st. The shares were acquired at an average price of $16.00 per share, with a total value of $8,000,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 961,424 shares of company stock valued at $15,382,784 in the last quarter.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: Leveraged Buyout (LBO) Explained

The Fly

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with's FREE daily email newsletter.